Literature DB >> 23797772

Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients.

Zhengbo Song1, Huineng Zhu, Zhenying Guo, Wei Wu, Wenyong Sun, Yiping Zhang.   

Abstract

A new lung adenocarcinoma classification proposed by the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society (IASLC/ATS/ERS) has recently been published. However, the relationship between EGFR mutations and subtype of adenocarcinoma remains unclear. A total of 161 surgically resected lung adenocarcinomas in Zhejiang Cancer Hospital were reviewed using the new classification system. Epidermal growth factor receptor (EGFR) mutations were observed in 67 cases (41.6 %). EGFR mutations were found to be closely associated with the micropapillary predominant subtype (P = 0.0068) and lepidic component (P = 0.005). The frequency of EGFR mutation was found to be lower in the solid predominant subtype than other subtype (P = 0.04). In conclusion, histologic subtyping was found to be associated with EGFR mutations. The EGFR mutation frequency of micropapillary and lepidic predominant subtypes was found to be more pronounced than that of other subtypes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23797772     DOI: 10.1007/s12032-013-0645-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  8 in total

1.  Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.

Authors:  Yang Zhang; Yihua Sun; Yunjian Pan; Chenguang Li; Lei Shen; Yuan Li; Xiaoyang Luo; Ting Ye; Rui Wang; Haichuan Hu; Hang Li; Lei Wang; William Pao; Haiquan Chen
Journal:  Clin Cancer Res       Date:  2012-02-08       Impact factor: 12.531

2.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

3.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors:  Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

4.  Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.

Authors:  Rebecca Siegel; Elizabeth Ward; Otis Brawley; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2011-06-17       Impact factor: 508.702

Review 5.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

6.  High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.

Authors:  Ping-Li Sun; Hyesil Seol; Hyun Ju Lee; Seol Bong Yoo; Hyojin Kim; Xianhua Xu; Sanghoon Jheon; Choon-Taek Lee; Jong-Suk Lee; Jin-Haeng Chung
Journal:  J Thorac Oncol       Date:  2012-02       Impact factor: 15.609

7.  Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification.

Authors:  Hyo Sup Shim; Da Hye Lee; Eun Ju Park; Se Hoon Kim
Journal:  Arch Pathol Lab Med       Date:  2011-10       Impact factor: 5.534

8.  Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.

Authors:  Prudence A Russell; Stephen A Barnett; Marzena Walkiewicz; Zoe Wainer; Matthew Conron; Gavin M Wright; Julian Gooi; Simon Knight; Rochelle Wynne; Danny Liew; Thomas John
Journal:  J Thorac Oncol       Date:  2013-04       Impact factor: 15.609

  8 in total
  34 in total

1.  Association between the CpG island methylator phenotype and its prognostic significance in primary pulmonary adenocarcinoma.

Authors:  Young Wha Koh; Sung-Min Chun; Young-Soo Park; Joon Seon Song; Geon Kook Lee; Shin Kwang Khang; Se Jin Jang
Journal:  Tumour Biol       Date:  2016-02-11

2.  Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification of lung adenocarcinoma.

Authors:  Zhen Chen; Xiaoyan Liu; Jing Zhao; Hanjin Yang; Xiaodong Teng
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 3.  Advances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system (IASLC/ATS/ERS).

Authors:  Elizabeth R Tang; Andrew M Schreiner; Bradley B Pua
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 4.  The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects.

Authors:  Jon Zugazagoitia; Ana Belen Enguita; Juan Antonio Nuñez; Lara Iglesias; Santiago Ponce
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 5.  Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts.

Authors:  Ming-Ching Lee; Kyuichi Kadota; Daniel Buitrago; David R Jones; Prasad S Adusumilli
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

6.  The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know.

Authors:  Takashi Eguchi; Kyuichi Kadota; Bernard J Park; William D Travis; David R Jones; Prasad S Adusumilli
Journal:  Semin Thorac Cardiovasc Surg       Date:  2014-09-16

7.  Epidermal growth factor receptor mutations in lung adenocarcinoma: associations between dual-energy spectral CT measurements and histologic results.

Authors:  Guojin Zhang; Junlin Zhou; Yuntai Cao; Jing Zhang; Zhiyong Zhao; Wenjuan Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-26       Impact factor: 4.553

8.  CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.

Authors:  Ying Liu; Jongphil Kim; Fangyuan Qu; Shichang Liu; Hua Wang; Yoganand Balagurunathan; Zhaoxiang Ye; Robert J Gillies
Journal:  Radiology       Date:  2016-03-03       Impact factor: 11.105

9.  Prognostic value of epidermal growth factor receptor mutations and histologic subtypes with lung adenocarcinoma.

Authors:  Nozomu Motono; Aika Funasaki; Atsushi Sekimura; Katsuo Usuda; Hidetaka Uramoto
Journal:  Med Oncol       Date:  2018-01-31       Impact factor: 3.064

Review 10.  Surgical pathology of early stage non-small cell lung carcinoma.

Authors:  Mary Beth Beasley; Francine R Dembitzer; Raja M Flores
Journal:  Ann Transl Med       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.